Advanced Filters
noise

Peripheral Arterial Occlusive Disease Clinical Trials

A listing of Peripheral Arterial Occlusive Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 276 clinical trials
A Anh Lam

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer

18 years of age All Phase 2

Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP

Aim to investigate the effect of Letrozole as maintenance after adjuvant treatment on the prognosis of post-operative endometrial cancer patients with non-specific molecular profile.

18 - 80 years of age Female Phase 2/3

A Study of a Weight Loss Intervention in People With Endometrial Cancer

The researchers are doing this study is to find out whether tirzepatide and semaglutide are practical (feasible) for weight management and blood sugar control for endometrial cancer patients undergoing chemotherapy. The researchers will also look at participants' experience with the study drug, the safety of taking the study drug while …

18 years of age Female Phase N/A
F FRANCESCO CUCCIA, MD

a SIngle Center Study of Post-operative STEReotactic RAdiotherapY for Endometrial Cancer

The primary endpoint of the present prospective study is to assess the outcomes in terms of acute toxicity of post-operative stereotactic radiotherapy for endometrial cancer

18 - 80 years of age Female Phase N/A

QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer

This is a prospective, single-arm, multicenter Phase II study evaluating the efficacy and safety of QL1706 combined with chemotherapy in patients with advanced recurrent or metastatic endometrial cancer who progressed after prior anti-PD-1/L1 therapy.

18 - 70 years of age Female Phase 2

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order …

18 years of age Female Phase 1/2
X Xiaojun Chen, PhD

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

To investigate the efficacy of GnRHa plus letrozole vs Diane-35 plus metformin in non-obese progestin-insensitive early-stage endometrial cancer (EEC) and atypical hyperplasia(EAH) patients asking for conservative treatment.

18 - 45 years of age Female Phase 2/3
J Jianbing Hu

Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

This is an open-label, multi-center, multi-corhort Phase II study of Envafolimab alone or with Lenvatinib in patients with advanced endometrial cancer.The primary objective is to evaluate objective response rate of envafolimab alone or with lenvatinib.

18 years of age Female Phase 2
X Xiaorong Hou, Professor

Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer

Study Type: Single-center, single-arm, prospective study. Sample Size: 20 patients with high-risk endometrial cancer were enrolled. Treatment Procedure: The existing clinical oART (Online Adaptive Radiotherapy) workflow protocol for malignant tumors used in our department was applied. Procedures included simulation, target volume delineation, radiotherapy planning, and treatment delivery. External beam radiation …

18 - 70 years of age Female Phase N/A

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.

18 - 70 years of age Female Phase 2

Simplify language using AI